Celldex Therapeutics, Inc. (NASDAQ:CLDX) Given Consensus Rating of “Moderate Buy” by Analysts

Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX) have received an average rating of “Moderate Buy” from the five brokerages that are covering the firm, Marketbeat reports. One investment analyst has rated the stock with a hold rating and four have issued a buy rating on the company. The average 1-year price target among analysts that have issued ratings on the stock in the last year is $66.00.

Several equities analysts have commented on CLDX shares. Cantor Fitzgerald reissued an “overweight” rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Friday, March 22nd. Guggenheim lifted their target price on shares of Celldex Therapeutics from $72.00 to $90.00 and gave the stock a “buy” rating in a research report on Tuesday, February 27th. Finally, HC Wainwright restated a “buy” rating and set a $80.00 price target on shares of Celldex Therapeutics in a research note on Wednesday, April 17th.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of CLDX. Eventide Asset Management LLC grew its stake in Celldex Therapeutics by 126.9% in the 4th quarter. Eventide Asset Management LLC now owns 3,630,013 shares of the biopharmaceutical company’s stock valued at $143,966,000 after buying an additional 2,030,013 shares in the last quarter. Point72 Asset Management L.P. grew its stake in Celldex Therapeutics by 105.3% in the 4th quarter. Point72 Asset Management L.P. now owns 2,756,122 shares of the biopharmaceutical company’s stock valued at $109,308,000 after buying an additional 1,413,722 shares in the last quarter. Wellington Management Group LLP grew its stake in Celldex Therapeutics by 19.2% in the 4th quarter. Wellington Management Group LLP now owns 6,476,561 shares of the biopharmaceutical company’s stock valued at $256,860,000 after buying an additional 1,044,728 shares in the last quarter. Kynam Capital Management LP grew its stake in Celldex Therapeutics by 23.1% in the 3rd quarter. Kynam Capital Management LP now owns 3,200,000 shares of the biopharmaceutical company’s stock valued at $88,064,000 after buying an additional 600,000 shares in the last quarter. Finally, Bellevue Group AG grew its stake in Celldex Therapeutics by 27.2% in the 4th quarter. Bellevue Group AG now owns 2,416,296 shares of the biopharmaceutical company’s stock valued at $95,830,000 after buying an additional 516,296 shares in the last quarter.

Celldex Therapeutics Stock Performance

Shares of NASDAQ CLDX opened at $37.77 on Wednesday. Celldex Therapeutics has a fifty-two week low of $22.11 and a fifty-two week high of $53.18. The firm’s 50-day simple moving average is $42.11 and its 200 day simple moving average is $36.08. The stock has a market cap of $2.11 billion, a price-to-earnings ratio of -12.98 and a beta of 1.50.

Celldex Therapeutics (NASDAQ:CLDX) last posted its earnings results on Monday, February 26th. The biopharmaceutical company reported ($0.57) EPS for the quarter, topping the consensus estimate of ($0.76) by $0.19. Celldex Therapeutics had a negative net margin of 2,054.46% and a negative return on equity of 41.06%. The firm had revenue of $4.13 million for the quarter, compared to analysts’ expectations of $1.20 million. On average, sell-side analysts predict that Celldex Therapeutics will post -2.85 EPS for the current year.

Celldex Therapeutics Company Profile

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.